

27 May 2009

Proposal for Mylan risperidone, lithium carbonate and quetiapine

PHARMAC is seeking feedback on a proposal to fund a new brand of risperidone oral liquid (Risperon), and to amend the terms of listing of the Lithicarb brand of lithium carbonate and the Quetapel brand of quetiapine, through a provisional agreement with Mylan New Zealand Ltd.

Details of this proposal can be found below and on the following page.

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Friday, 12 June 2009** to:

Geraldine MacGibbon
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: geraldine.macgibbon@pharmac.govt.nz

Fax: (04) 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Details of the proposal

From 1 October 2009, Risperon (risperidone) oral liquid 1 mg per ml would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule at a price and subsidy of \$18.35 per 30 ml (ex-manufacturer, excluding GST). Risperon would have protection from delisting and subsidy reduction until 1 July 2012.

From 1 August 2009, the price and subsidy for Lithicarb (lithium carbonate) tablets would increase in Section B of the Pharmaceutical Schedule as outlined in the following table (prices and subsidies expressed ex-manufacturer, excluding GST). Lithicarb would have protection from delisting and subsidy reduction until 1 July 2012.

Pharmaceutical	Brand	Form and Strength	Pack Size	Current price and subsidy	Proposed price and subsidy
Lithium carbonate	Lithicarb	Tablet 250 mg	500	\$25.45	\$36.10
Lithium carbonate	Lithicarb	Tablet 400 mg	100	\$9.17	\$13.50

From 1 December 2009, the price and subsidy for Quetapel (quetiapine) tablets would reduce in Section B and in Part II of Section H of the Pharmaceutical Schedule as outlined in the following table (prices and subsidies expressed ex-manufacturer, excluding GST). Quetapel would have protection from delisting and subsidy reduction until 1 July 2012.

Pharmaceutical	Brand	Form and Strength	Pack Size	Current price and subsidy	Proposed price and subsidy
Quetiapine	Quetapel	Tablet 25 mg	90	\$20.62	\$16.78
Quetiapine	Quetapel	Tablet 100 mg	90	\$41.25	\$32.59
Quetiapine	Quetapel	Tablet 200 mg	90	\$70.88	\$56.70
Quetiapine	Quetapel	Tablet 300 mg	90	\$119.25	\$95.40